Dr. Anahita Keyhani Joins Algorithme Pharma Laboratory Leadership as Director, Method Development

(Laval, Québec, Canada, July 15, 2015) – Algorithme Pharma, a full service provider focused on early stage clinical research with over twenty years of experience, proudly announces the addition of Dr. Anahita Keyhani to the Algorithme Pharma family. Dr. Keyhani brings almost two decades of experience to her new role as Director, Method Development, previously Senior Research Scientist at Charles River Laboratories. "Dr. Keyhani is an experienced Bioanalytical Scientist with a proven record in regulated laboratory study management in both preclinical and clinical development. Her ability to maintain strong client relationships, manage complex projects, work and adapt to cutting-edge technology, and rally her peers, will be of great value to our large team of highly competent scientific experts. We are confident that her contribution is a perfect match for what we do best: offering scientific excellence, uncompromised quality and unbeatable timelines to meet and exceed our clients’ needs." said Chris Perkin, Chief Executive Officer. “She will play a key role in our ongoing strategy to be the best in the business of method development for innovator drugs, both small and large molecules.” Algorithme Pharma is the largest privately held Québec-owned organization specializing in clinical research services for the international pharmaceutical industry. In addition to Bioanalysis, their support services include Data Management, Biostatistics, Regulatory Support, Clinical Pharmacology and Project Management. They operate out of Montréal, Québec, and Fargo, North Dakota. About Altasciences Altasciences, owned by Kilmer Capital Partners, owns Algorithme Pharma, Algorithme Pharma USA and Vince & Associates Clinical Research. All organizations operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service. FOR MORE INFORMATION Amy Sikora Director, Communications and Marketing [email protected] 514 210-6993

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.